FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068236212> ?p ?o ?g. }

• W2068236212 endingPage "180" @default.
• W2068236212 startingPage "171" @default.
• W2068236212 abstract "Two different strategies, referred to as gastrointestinal (GI) preventive therapy (GIPT), have been recommended for high-risk patients to prevent GI complications associated with antiarthritic therapy with nonsteroidal anti-inflammatory drugs (NSAIDs): (1) use of a gastroprotective agent (GPA) along with the NSAID or (2) use of a cyclooxygenase-2-selective inhibitor (COX-2SI). The COX-2SIs rofecoxib and celecoxib have been shown to be as effective as traditional NSAADs for pain relief, but with an improved GI safety profile.The purpose of this study was to examine the utilization of GIPT by elderly persons in Nova Scotia who were taking antiarthritic medications and to identify the factors associated with their use of GIPT.A retrospective, cross-sectional study was conducted using administrative data from the Nova Scotia Seniors' Pharmacare Program database. Study participants were aged >or=65 years and had filled a prescription for a COX-2SI, a traditional NSAID, or high-dose aspirin at some point between January 1, 2001 and August 31, 2002. Subjects with at least 1 risk factor (as defined by our study) who received GIPT were classified as receiving appropriate therapy. Subjects with risk factors who did not receive GIPT were classified as potential underutilizers of GIPT. Subjects without risk factors who received GIPT were classified as potential overutilizers of GIPT. Descriptive statistics were presented, and factors independently associated with receiving GIPT were assessed using logistic regression.The study included 14,587 seniors: 3647 used COX-2SIs, 9412 used traditional NSAIDs alone, and 1528 used traditional NSAADs plus a GPA. Subjects were predominantly female (age range, 65-74 years). In subjects with at least 1 risk factor, 63% were classified as potential underutilizers of GIPT. Thirty-three percent of subjects with no risk factors were classified as potential overutilizers of GIPT. Factors significantly associated with receiving a GIPT included Female gender, annual income >$50,000, urban residence, age >or=75 years, GI complication in the previous year, and concomitant use of warfarin or corticosteroids.Potential under utilization of GIPT in this subject population was more prevalent than potential overutilization of GIPT. Although all hypothesized risk factors were significantly associated with receiving GIPT, physician education on GI risk factors might improve prescribing of GIPT for elderly persons in Nova Scotia." @default.
• W2068236212 created "2016-06-24" @default.
• W2068236212 creator A5005248039 @default.
• W2068236212 creator A5044373576 @default.
• W2068236212 creator A5050538421 @default.
• W2068236212 creator A5050560181 @default.
• W2068236212 date "2004-09-01" @default.
• W2068236212 modified "2023-10-10" @default.
• W2068236212 title "Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada" @default.
• W2068236212 cites W1926898034 @default.
• W2068236212 cites W1931694716 @default.
• W2068236212 cites W1964040308 @default.
• W2068236212 cites W1967276177 @default.
• W2068236212 cites W1976461877 @default.
• W2068236212 cites W2001350224 @default.
• W2068236212 cites W2034013987 @default.
• W2068236212 cites W2050784884 @default.
• W2068236212 cites W2092787846 @default.
• W2068236212 cites W2102307364 @default.
• W2068236212 cites W2110739516 @default.
• W2068236212 cites W2134236228 @default.
• W2068236212 cites W2157452732 @default.
• W2068236212 cites W2163756514 @default.
• W2068236212 cites W2166587212 @default.
• W2068236212 cites W2328392888 @default.
• W2068236212 cites W2330496155 @default.
• W2068236212 cites W2339181429 @default.
• W2068236212 cites W2339197236 @default.
• W2068236212 cites W334564628 @default.
• W2068236212 cites W4361867558 @default.
• W2068236212 doi "https://doi.org/10.1016/j.amjopharm.2004.09.001" @default.
• W2068236212 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15561649" @default.
• W2068236212 hasPublicationYear "2004" @default.
• W2068236212 type Work @default.
• W2068236212 sameAs 2068236212 @default.
• W2068236212 citedByCount "21" @default.
• W2068236212 countsByYear W20682362122012 @default.
• W2068236212 countsByYear W20682362122013 @default.
• W2068236212 countsByYear W20682362122015 @default.
• W2068236212 crossrefType "journal-article" @default.
• W2068236212 hasAuthorship W2068236212A5005248039 @default.
• W2068236212 hasAuthorship W2068236212A5044373576 @default.
• W2068236212 hasAuthorship W2068236212A5050538421 @default.
• W2068236212 hasAuthorship W2068236212A5050560181 @default.
• W2068236212 hasConcept C126322002 @default.
• W2068236212 hasConcept C151956035 @default.
• W2068236212 hasConcept C166957645 @default.
• W2068236212 hasConcept C167135981 @default.
• W2068236212 hasConcept C181199279 @default.
• W2068236212 hasConcept C185592680 @default.
• W2068236212 hasConcept C2426938 @default.
• W2068236212 hasConcept C2776467144 @default.
• W2068236212 hasConcept C2777628954 @default.
• W2068236212 hasConcept C2778582115 @default.
• W2068236212 hasConcept C2779689624 @default.
• W2068236212 hasConcept C2988919728 @default.
• W2068236212 hasConcept C50382708 @default.
• W2068236212 hasConcept C50440223 @default.
• W2068236212 hasConcept C55493867 @default.
• W2068236212 hasConcept C71924100 @default.
• W2068236212 hasConcept C95457728 @default.
• W2068236212 hasConcept C98274493 @default.
• W2068236212 hasConceptScore W2068236212C126322002 @default.
• W2068236212 hasConceptScore W2068236212C151956035 @default.
• W2068236212 hasConceptScore W2068236212C166957645 @default.
• W2068236212 hasConceptScore W2068236212C167135981 @default.
• W2068236212 hasConceptScore W2068236212C181199279 @default.
• W2068236212 hasConceptScore W2068236212C185592680 @default.
• W2068236212 hasConceptScore W2068236212C2426938 @default.
• W2068236212 hasConceptScore W2068236212C2776467144 @default.
• W2068236212 hasConceptScore W2068236212C2777628954 @default.
• W2068236212 hasConceptScore W2068236212C2778582115 @default.
• W2068236212 hasConceptScore W2068236212C2779689624 @default.
• W2068236212 hasConceptScore W2068236212C2988919728 @default.
• W2068236212 hasConceptScore W2068236212C50382708 @default.
• W2068236212 hasConceptScore W2068236212C50440223 @default.
• W2068236212 hasConceptScore W2068236212C55493867 @default.
• W2068236212 hasConceptScore W2068236212C71924100 @default.
• W2068236212 hasConceptScore W2068236212C95457728 @default.
• W2068236212 hasConceptScore W2068236212C98274493 @default.
• W2068236212 hasIssue "3" @default.
• W2068236212 hasLocation W20682362121 @default.
• W2068236212 hasLocation W20682362122 @default.
• W2068236212 hasOpenAccess W2068236212 @default.
• W2068236212 hasPrimaryLocation W20682362121 @default.
• W2068236212 hasRelatedWork W2030674475 @default.
• W2068236212 hasRelatedWork W2040872866 @default.
• W2068236212 hasRelatedWork W2045966064 @default.
• W2068236212 hasRelatedWork W2065689558 @default.
• W2068236212 hasRelatedWork W2078054293 @default.
• W2068236212 hasRelatedWork W2080725400 @default.
• W2068236212 hasRelatedWork W2084229613 @default.
• W2068236212 hasRelatedWork W2102307364 @default.
• W2068236212 hasRelatedWork W1644577377 @default.
• W2068236212 hasRelatedWork W2554036459 @default.
• W2068236212 hasVolume "2" @default.
• W2068236212 isParatext "false" @default.
• W2068236212 isRetracted "false" @default.

• next